Case Study | May 11, 2011

Relay stent-grafts show promise in treatment of aortic dissection patients

Aortic dissection is rare, but when it occurs, a patient’s prognosis can be poor, even with timely medical diagnosis and treatment. It is the most frequently diagnosed lethal condition of the aorta. In the past, a type A dissection had been treated with surgery and a type B dissection with drugs to lower blood pressure and heart rate. Another option, thoracic endovascular aortic repair (TEVAR), where a stent-graft is placed inside the aorta, was introduced in 1999. This procedure restores the normal aortic anatomy to prevent aortic expansion or rupture.

A study in the April issue of the Journal of Endovascular Therapy evaluates the performance of a specific stent-graft, the Relay thoracic stent-graft, made by Bolton Medical SL. Ninety-one patients who had received this treatment were identified from the Relay Endovascular Registry for Thoracic Disease (RESTORE) database—a multicenter clinical registry in Europe where the Relay stents are currently available. Study subjects were followed for two years after the procedure.

The current study included 69 men and 22 women with a mean age of 65 years who underwent TEVAR using a Relay stent-graft. The technical success rate was 95 percent. The 30-day mortality rate was 8 percent. Over the long term, an 82 percent survival rate was seen in the 2-year period following the procedure.

Seventy-six participants in the Relay study population had type B dissections. Long-term survival has been a particular challenge for patients with type B dissections. The two-year survival rate for type B patients in this study was 84 percent.

Among the risks of TEVAR are stroke and spinal cord injury. A 4 percent occurrence of paraplegia and a low 2 percent incidence of stroke were found in this study sample. These numbers are comparable with several other studies involving larger populations of patients and other stent-grafts.

The authors conclude that “the combination of Relay’s features, such as high stent conformability, low stent radial force, smooth and atraumatic design, controlled deployment, and fixation by its proximal capture mechanism, suggest that TEVAR using Relay devices is a feasible and safe procedure for the endovascular treatment of aortic dissections, including acute and chronic type B dissections.”

For more information:www.jevtonline.org/doi/full/10.1583/10-3233MR.1

Related Content

News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
Overlay Init